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Pilot study: assessing the clinical 
diagnosis of allergy in atopic children using  
a microarray assay in addition to  
skin prick testing and serum specific IgE
Ru‑Xin Foong1,2*, Graham Roberts3, Adam Tobias Fox1 and George du Toit1
Abstract 
Background: Children with atopic dermatitis (AD) are at risk of developing allergy. Alongside clinical history, testing 
modalities include skin prick tests (SPT), specific immunoglobulin‑E (sp‑IgE) and recently, microarray assays. The aim 
of this pilot study was to assess current tests and the ISAC sIgE‑112 system in the diagnosis of food and aeroallergen 
allergy.
Methods: Children aged 0–11 years with moderate to severe AD were included. An initial allergy assessment includ‑
ing clinical history, SPT and sp‑IgE was performed to determine food and aeroallergen sensitization. A second inde‑
pendent clinical assessment using the same information given to the first assessor and ISAC test results for food and 
aeroallergen sensitization was also made for each participant. The results from both were compared.
Results: 30 children [mean age 3.91 years (SD 3.3)] were included; 53.3 and 46.7 % had moderate and severe AD, 
respectively. Sp‑IgE tests had a higher percentage of positive results compared to SPT and ISAC tests for com‑
mon allergens. There was a significant difference between the three tests in detecting aeroallergen sensitization 
(p = 0.038), especially between sp‑IgE and ISAC tests, but no significant difference between the tests for food allergen 
sensitization. There was good agreement between the two assessors; 70 % of the children had a change in diagnosis, 
with 60 % having at least one diagnosis added and 40 % having at least one diagnosis removed.
Conclusions: There is a role for the use of ISAC testing in diagnosing sensitization and allergy in children with AD as 
it leads to a change in diagnosis for many patients. Further work is required to assess its clinical and cost effectiveness.
Keywords: Aeroallergens, Atopic dermatitis, Diagnostic investigations, Food allergy
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Background
Atopic dermatitis (AD) is a common inflammatory skin 
disease affecting 15–20 % of children in developed coun-
tries [1]. It usually starts in the first few months of life and 
is frequently outgrown by 15 years of age although there 
is a large amount of variability between children [2].
It is well known that there are close links between food 
allergy and AD as it is a significant risk factor for the 
development of food sensitization and food allergy [2–4]. 
Patients with higher levels of total Immunoglobulin-E 
(IgE) in their blood, which is often the case in children 
with AD, are more likely to be sensitised to foods [1, 5]. 
Kumar et al. found that children with AD had an 8.4-fold 
higher risk of developing a food allergy [6]. de Benedic-
tis et al. demonstrated that of infants with AD in various 
countries around the world, 55.5 % were sensitised to at 
least one allergen and 52.9 % had a raised serum total IgE 
[7].
Due to the increased likelihood of children with AD 
being sensitised to various food allergens, it can be dif-
ficult to establish whether these children have true food 
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allergy. The European Academy of Allergy and Clinical 
Immunology (EAACI) guidelines recommend the use of 
clinical history, skin prick tests (SPT) and serum specific 
IgE (sp-IgE) tests in the investigation of food allergy but 
the gold standard for diagnosis remains the oral food 
challenge [8]. AD is often associated with aeroallergen 
sensitization and in the context of a high level of total 
IgE, there are often low levels of sp-IgE to numerous aer-
oallergens [1]. These are of unclear clinical significance.
Immunocap® ISAC-112 (Thermo Fisher/Phadia AB, 
Uppsala, Sweden) is an in  vitro assay for the measure-
ment of allergen sp-IgE antibodies in human plasma [9]. 
It is intended to aid in the diagnosis of IgE-mediated 
allergic disorders. There is currently no advice on the use 
of ISAC testing worldwide [8, 10]. The National Institute 
of Allergy and Infectious Diseases (NIAID) guidelines do 
not recommend the combined use of SPTs and sp-IgE 
tests for routine diagnosis of food allergy and instead rec-
ommend individual SPT and sp-IgE tests to help identify 
foods that might be provoking a reaction alongside clini-
cal history [10]. Thus, the utilization of a broad screen-
ing test is controversial. Whilst it may facilitate a more 
accurate clinical allergy diagnosis for specific atopic 
conditions [11, 12], it has been suggested that identify-
ing patterns of allergen responses for patients with AD 
is less reliable [12]. Spergel et al. [13] found that the pre-
dictive values of food-antigen sp-IgE were not clinically 
significant in predicting the development of food allergy 
in children with mild to moderate AD. However, this 
study performed sp-IgE only for common food allergens, 
potentially missing less common allergens [13].
The ISAC-112 has the potential as a single test modal-
ity, to identify food and aeroallergen sensitizations in at 
risk atopic children. Hatzler et al. [14] looked at the IgE 
response to grass pollen antigens and demonstrated that 
sensitization can occur years before the onset of clinical 
disease through a process called “molecular spreading”. 
Therefore, the use of microarrays could be convenient in 
the setting where common food allergens have not yet 
been introduced thereby limiting the value of a detailed 
clinical history.
The aim of this pilot study was to assess the use of cur-
rent diagnostic modalities (clinical consultation, SPT, sp-
IgE) in a specialist allergy clinic in children with AD. We 
also assessed whether Immunocap® ISAC sIgE-112 test-
ing could improve the diagnosis of food and aeroallergen 
allergy in these children.
Methods
Participants
We recruited children aged 0–11 years from the paediat-
ric allergy clinic at St. Thomas’ Hospital, London UK, an 
urban, tertiary referral centre. We identified children who 
had moderate to severe AD using any one of the LEAP 
study criteria [15]: parents or guardians’ description of 
their child’s AD severity as moderate or severe; use of 
topical creams and ointments containing corticosteroids 
or calcineurin inhibitors (defined as severe); or modified 
Scoring Atopic Dermatitis System (SCORAD) evaluation 
of at least 15 [16]. Written consent was obtained from the 
parents and child (if age relevant). Ethics approval was 
given by the NRES Committee London—Fulham (12/
LO/1733).
Initial allergy assessment
The participants who fitted the criteria for moderate to 
severe AD underwent a detailed allergy clinical assess-
ment (clinical history, SPT, sp-IgE tests) by a paediatric 
allergy consultant. A clinical diagnosis of food allergy and 
clinically significant aeroallergen sensitization was made 
based on these findings. The most common food and aer-
oallergens were tested for: peanut (Ara h1, Ara h2, Ara 
h3, Ara h8, Ara h9), egg (white or yolk), cow’s milk, timo-
thy grass pollen, birch tree pollen, Dermatophagoides 
pteronyssinus house dust mite, Alternaria mould, cat and 
dog. SPT were performed using Alyostal® Stallergenes 
allergen extracts by trained paediatric allergy nurses 
in the department. Sensitization to food and aeroal-
lergens to the same allergens was measured by specific-
IgE (Thermo Fisher, Uppsala, Sweden). Food allergy was 
defined by a history of IgE-mediated symptoms (e.g. rash, 
urticaria, wheeze, vomiting, hypotension, anaphylaxis) 
on exposure to a food antigen, in the presence of a posi-
tive SPT (≥3 mm) or sp-IgE (≥0.35 kU/l) [17]. Clinically 
significant aeroallergen sensitization was defined as posi-
tive SPT (≥3 mm) or sp-IgE (∓0.35 kU/l) in the presence 
of a history of worsening AD, allergic rhino-conjuncti-
vitis or asthma symptoms when exposed to the relevant 
aeroallergen.
Second allergy assessment with ISAC
All participants then had an ISAC-112 (Thermo Fisher 
Scientific©) test performed of which blood was taken 
after the clinic appointment. Immunocap and ISAC-112 
analysis were processed by the Viapath Analytics depart-
ment at King’s College Hospital, London UK. A positive 
ISAC was defined as ≥0.3 ISU-E for the same allergens 
tested for in the initial assessment. A second assessment 
was performed by a second paediatric allergy consult-
ant who used the clinical history, SPT, sp-IgE and ISAC 
results to make an independent clinical assessment of the 
presence of food allergy and aeroallergen sensitizations.
Statistics
Statistical analysis was performed using (STATA, ver-
sion 14, College Station, USA). Descriptive statistics were 
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presented as means with standard deviation (SD) where 
appropriate and categorical variables presented as per-
centages. Kappa statistics were used to look at agreement 
between the tests results and allergic diagnoses. A Kappa 
of 0.01–0.4 is considered slight to fair agreement, 0.41–
0.60 is moderate agreement and 0.61–0.99 is substantial 
to almost perfect agreement [18]. Chi square tests were 
used to compare the proportion sensitised to food aller-
gens and aeroallergens based on the test performed. To 
compare the number of allergens that were positive for 
each participant for the difference tests and number 
of allergic diagnoses per participant, repeat measures 
ANOVA tests were used.
Results
A total of 30 participants were recruited for this study. 
The mean age of the children was 3.91 years (SD 3.3) and 
60 % (n = 18) were male. Of the group, 53.3 % (n = 16) 
and 46.7  % (n =  14) had SCORAD scores suggestive of 
moderate and severe AD, respectively.
Comparison of SPT, sp‑IgE and ISAC tests
We compared the percentage of children who had a posi-
tive test result on SPT, sp-IgE and ISAC for common 
food and aeroallergens (Fig.  1). Overall, apart from egg 
allergen, the sp-IgE tests had a higher percentage of posi-
tive results for each allergen compared to SPT and ISAC 
tests. When comparing SPT and ISAC tests a relatively 
similar percentage of positive results for allergens were 
noted. For example, for birch pollen, 36 % had a positive 
SPT and 36.7 % had a positive ISAC test.
We also looked at the agreement between the three dif-
ferent tests (Table 1). There was good agreement between 
the SPT and ISAC tests for sensitization to selected 
food and aeroallergens. There was relatively good agree-
ment between sp-IgE and ISAC tests for house dust mite 
and Alternaria mould. There was also good agreement 
between SPT and sp-IgE for house dust mite. Other 
test and allergen comparisons showed low levels of 
agreement.
Comparison of positive sensitizations for each participant
The number of positive sensitizations for each partici-
pant for each test was compared. For aeroallergens, over-
all there was a significant difference between the results 
of the three tests (p = 0.038); subsequent pairwise com-
parisons found that the only significant difference was 
between the sp-IgE and ISAC tests results (Table 2). For 
food allergens, there was no overall significant differ-
ence found between the results from the different tests 
(p =  0.469). These results do require further considera-
tion in the context of the specificity of the tests.
More specifically, we compared each participant’s posi-
tive sensitizations based on the test performed. We found 
that 73.3  % of the participants had at least one posi-
tive aeroallergen based on their ISAC test compared to 
both their SPT or sp-IgE results, although the difference 
was not statistically significant (p =  0.35). For the food 















Sensitisation to common allergens based on type of test 
SPT
Fig. 1 Sensitization to common allergens based on the type of test performed. Figures are numerator/denominator (%) positive for each test for 
allergic sensitisation. Positive SPT was defined as ≥3 mm, positive specific IgE as ≥0.35 kU/l and positive ISAC as ≥0.3 ISU‑E
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allergens, 76.7 and 73.3 % of participants were identified 
as sensitised by SPT or sp-IgE tests, respectively, com-
pared to their ISAC test but the difference was not sig-
nificant (p = 0.50).
Comparison of allergy diagnoses between the two 
assessors
We then compared allergy diagnoses outcomes between 
the two different assessors (Table 3). Overall, we found 
relatively good agreement between the two assessors. 
There was higher agreement for the food allergens 
compared to the aeroallergens except for house dust 
mite and Alternaria mould allergy (k  =  0.92 and 
k =  0.70, respectively). The mean number of allergies 
diagnosed by assessor 1 was 5.3 (SD 2.56) and was 5.9 
(SD 2.98) by assessor 2, which were not significantly dif-
ferent (p = 0.20). The distribution of numbers of allergy 
diagnoses for the two assessors is presented in Table 3. 
There was no significant difference found between 
the number of allergy diagnoses for food allergens 
(p  =  0.214) or aeroallergens (p  =  0.588) between the 
two assessors.
As assessment 2 was made with the addition of the 
ISAC results, we were able to observe the effect the 
ISAC test had on allergy diagnoses (Table  4). When 
considering specific allergen diagnoses, a total of 20 
diagnoses were removed based on the inclusion of 
ISAC results and 26 allergen diagnoses were added; 13 
of those added were for food allergens not included in 
the SPT or sp-IgE screens. We found that 70 % (21/30) 
of the participants had a change in diagnosis between 
their two assessments with 60 % (18/30) having at least 
one allergic diagnosis added and 40 % (12/30) having at 
least one allergic diagnosis removed (Additional file 1: 
Table S1).
With regards to atopy, all the patients had a diagnosis 
of AD; therefore, there was 100  % agreement between 
the assessors (k =  1.00). For rhino-conjunctivitis, there 
were six diagnoses that were removed by assessor 2 and 
replaced by a diagnosis of non-allergic rhino-conjunctivi-
tis. For asthma, there was no change with regards to diag-
nosis (k = 0.42) (Table 4).
Table 1 Agreement between the tests based on sensitiza-
tion
Figures are Kappa statistics (p values) where represent the level of agreement 
between allergen sensitization tests having taken into account any agreement 
that is expected by chance. Results of 0.61–0.99 signify excellent agreement, 
0.41–0.60 signifies moderate agreement and 0.01–0.4 signifies only slight to fair 
agreement [18]
Allergen SPT and IgE SPT and ISAC IgE and ISAC
Peanut 0.42 (0.02) 0.54 (0.003) 0.36 (0.023)
Egg 0.29 (0.072) 0.43 (0.01) 0.19 (0.148)
Cow’s milk 0.39 (0.010) 1.00 (<0.001) 0.38 (0.006)
Cat 0.53 (0.007) 0.86 (<0.001) 0.56 (0.003)
Dog 0.30 (0.029) 0.18 (0.192) 0.38 (0.008)
Birch pollen 0.20 (0.175) 0.65 (0.001) 0.55 (0.003)
Timothy grass pollen 0.28 (0.063) 0.73 (<0.001) 0.44 (0.005)
House dust mite 0.73 (<0.001) 0.58 (0.002) 0.92 (<0.001)
Alternaria mould −0.25 (0.855) 0.06 (0.390) 0.70 (<0.001)
Table 2 Number of  food and  aeroallergen sensitizations 
by participant based on the type of test performed
P values represent Chi square test. Given that this was significant for 
aeroallergens (*), pairwise comparisons were undertaken for aeroallergen 




SPT (%) Specific  
IgE (%)
ISAC (%) P value
Aeroallergens
0 13 (43.3) 9 (30.0) 8 (26.7) 0.038*
1 7 (23.3) 3 (10.0) 10 (33.3)
2 3 (10.0) 6 (20.0) 1 (3.3)
3 2 (6.7) 7 (23.3) 6 (20.0)
4 2 (6.7) 1 (3.3) 5 (16.7)
5 3 (10.0) 2 (6.7) 0 (0)
6 0 (0) 2 (6.7) 0 (0)
Food allergens
0 7 (23.3) 8 (26.7) 11 (36.7) 0.469
1 13 (43.3) 8 (26.7) 11 (36.7)
2 7 (23.3) 6 (20.0) 5 (16.7)
3 3 (10.0) 8 (26.7) 3 (10.0)









0 11 (36.7 %) 9 (30.0 %) 0.588
1 4 (13.3 %) 3 (10.0 %)
2 4 (13.3 %) 4 (13.3 %)
3 4 (13.3 %) 3 (10.0 %)
4 5 (16.7 %) 4 (13.3 %)
5 2 (6.7 %) 2 (6.7 %)
6 0 (0.0 %) 4 (13.3 %)
7 0 (0.0 %) 1(3.3 %)
Food allergens
0 3 (10.0 %) 3 (10.0 %) 0.214
1 7 (23.3 %) 13 (43.3 %)
2 11 (36.7 %) 4 (13.3 %)
3 7 (23.3 %) 6 (20.0 %)
4 2 (6.7 %) 4 (13.3 %)
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Discussion
There is little published data on the use of ISAC testing 
in AD children. Prosperi et al. [12] found that ISAC test-
ing had reasonable discrimination in detecting allergens 
associated with asthma, rhino-conjunctivitis, wheeze and 
airway hypersensitivity but it was not useful for detecting 
allergens associated with eczema in a paediatric cohort. 
Our study demonstrates that there is a high prevalence of 
food and aeroallergen sensitization in children with mod-
erate to severe AD. Although the use of the ISAC-112 
testing did not significantly change the number of allergic 
sensitizations or diagnoses compared to traditional test 
modalities of SPT and sp-IgE tests, the majority of par-
ticipants had a change in specific allergy diagnoses when 
all of the ISAC-112 results were utilized.
Our results demonstrate that for the food allergens 
tested, sp-IgE testing yielded more positive results as 
compared to SPT and ISAC, despite the ISAC test cover-
ing a greater array of pre-set food allergen components. 
It has been suggested that the binding characteristics of 
the ISAC-112 are more specific as they bypass the high 
rates of sensitization that can occur in AD children who 
have a raised total IgE. However, the number of food and 
aeroallergen sensitizations was not lower using ISAC 
tests, which suggests that the ISAC test may not circum-
vent this issue.
In recent years, several studies have been performed 
which demonstrate strong correlation between the ISAC-
112 test and other single-plex allergy tests (SPT, sp-IgE 
tests) [19, 20]. More specifically, studies have shown a 
good correlation between the testing methods for aeroal-
lergens such as grass pollens [21] and house dust mite in 
allergic rhinitis patients [11]. In our cohort, the results 
available from the ISAC-112 test resulted in a change in 
diagnosis of allergic rhino-conjunctivitis to non-allergic 
rhino-conjunctivitis for six children. This supports the 
view that the ISAC test may be helpful at differentiating 
between allergic and non-allergic rhino-conjunctivitis 
compared to clinical history and single-plex tests. In fact, 
the WAO-ARIA-GA2LEN consensus guidelines clarify 
the role that molecular allergy diagnostics such as ISAC-
112 can have on resolving genuine versus cross-reactive 
sensitization in poly-sensitized patients, such as those 
with AD; hence facilitating a more accurate assessment 
of the severity of risks to allergens [22].
Another consideration that allergy diagnostic centres 
may have is the cost of running these diagnostic tests. In 
our study, SPT cost £15.95 per vial of allergen solution 
(Alyostal® Stallergenes), which is used for approximately 
60 SPT (£0.27 per allergen per test). Skin prick testing 
requires a trained health care practitioner, safe medical 
facilities and time to perform and interpret the tests. Sp-
IgE tests cost £14.30 per allergen compared to the ISAC 
test, which costs £250 for 112 allergen components. 
Both of these tests require phlebotomy services, labora-
tory staff and the necessary laboratory equipment. For 
the patients with a clinical history that identifies likely 
target allergens, confirmation by SPT and sp-IgE testing 
may prove sufficient and more cost-effective. However, 
in the poly-sensitised allergic patient with no identifiable 
Table 4 Allergy assessment by two assessors
Percentages represent the number (%) of participants given each diagnoses by each assessor. The number (%) of participants who had each specific allergy diagnosis 
removed or added by assessor 2 (impact of the ISAC test results) is also presented. Level of agreement between assessors is presented as Kappa statistics (p values)








Atopic dermatitis 30 (100 %) 30 (100 %) 0 (0.0 %) 0 (0.0 %) 1.00
Rhino‑conjunctivitis 14 (46.7 %) 8 (26.7 %) 6 (20.0 %) 0 (0.0 %) 0.59 (<0.001)
Asthma 4 (13.3 %) 4 (13.3 %) 0 (0.0 %) 0 (0.0 %) 0.42 (0.010)
Peanut 13 (43.3 %) 13 (43.3 %) 0 (0.0 %) 1 (3.3 %) 0.73 (<0.001)
Egg 15 (50.0 %) 18 (60.0 %) 3 (10.0 %) 1 (3.3 %) 0.67 (<0.001)
Cow’s milk 9 (30.0 %) 7 (23.3 %) 1 (3.3 %) 1 (3.3 %) 0.66 (<0.001)
Other food allergy 21 (70.0 %) 19 (63.3 %) 1 (3.3 %) 13 (43.3 %) 0.85 (<0.001)
Cat 6 (20.0 %) 13 (43.3 %) 3 (10.0 %) 0 (0.0 %) 0.49 (0.001)
Dog 7 (23.3 %) 10 (33.3 %) 1 (3.3 %) 1 (3.3 %) 0.59 (<0.001)
House dust mite 11 (36.7 %) 17 (56.7 %) 2 (6.7 %) 2 (6.7 %) 0.49 (0.001)
Alternaria mould 6 (20.0 %) 10 (33.3 %) 1 (3.3 %) 2 (6.7 %) 0.67 (<0.001)
Birch pollen 10 (33.3 %) 13 (43.3 %) 1 (3.3 %) 2 (6.7 %) 0.79 (<0.001)
Timothy grass pollen 13 (43.3 %) 14 (46.7 %) 1 (3.3 %) 2 (6.7 %) 0.53 (0.002)
Horse 1 (3.3 %) 1 (3.3 %) 0 (0.0 %) 1 (3.3 %) −0.03 (0.575)
Total 14 (46.7 %) 26 (86.7 %)
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causative allergens, based on costing in our tertiary cen-
tre, the ISAC test would prove to be more cost effective 
if the clinician wanted to test for more than 18 aller-
gens or allergen components. Although this seems like 
a considerable number of allergens to test for, it is not 
an uncommon practice in investigating AD children. It 
is in the children with equivocal histories or poly-aller-
genicity that the ISAC test may provide clinicians with a 
more comprehensive overview of sensitization to com-
mon food and aeroallergens.
Limitations
The limitations of this study include small sample size 
recruited in a tertiary allergy clinic, which makes it difficult 
to extrapolate results to the general population. In smaller 
hospitals, ISAC testing may not be available which make 
these results less applicable to general clinical practice. 
However, our study focused on children with AD, which 
is an extremely common childhood atopic phenomena, of 
which allergic diagnoses can be challenging to diagnose. 
Although we tested for only a small number of allergens, 
these represent the most common food and aeroallergens 
in the UK. We assessed the additional diagnostic value of 
the ISAC-112 as opposed to the diagnostic performance of 
each of the modalities in isolation against a gold standard 
diagnostic provocation test. We also acknowledge that it 
would be beneficial to compare the different test modality 
outcomes for allergic diagnoses between AD children and 
a control population (i.e. children without AD) in future 
work. Also, the fact that the clinical examiners in this study 
were experienced specialist paediatric allergists can be 
seen as both an advantage and limitation of the study; this 
provides greater validity to the clinical diagnoses made, 
but different allergy tests may be interpreted differently in 
less experienced hands.
Conclusions
This pilot study demonstrates that there is a defined role 
for the use of ISAC testing in diagnosing sensitization 
and allergy in children with AD, which compares favour-
ably with existing modalities of testing (i.e. SPT, sp-IgE 
tests). Depending on the clinical setting and the patient 
population (i.e. those with AD), the ISAC test may be 
useful in leading to a change in diagnosis and be more 
cost effective. Further investigation in a larger popula-
tion, testing each test in isolation as well as against the 
gold standard (i.e. OFC), is needed.
Additional file
Additional file 1. Diagnoses for individual patients based on inclusion of 
all ISAC test results.
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